Immunohistochemistry analysis of treated tumors revealed that trametinib enhanced the rapamycin-mediated inhibition of S6 and 4E-BP1 in vivo, and blunted the rapamycin-induced ERK activation in these HNSCC cells (Figure 4A, 4B). Here, EIF4EBP1 is linked to head and neck squamous cell carcinoma.